CareDx Inc (CDNA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
CareDx Inc stock (CDNA) is currently trading at $17.84. CareDx Inc PS ratio (Price-to-Sales) is 2.32. Analyst consensus price target for CDNA is $24.80. WallStSmart rates CDNA as Sell.
- CDNA PE ratio analysis and historical PE chart
- CDNA PS ratio (Price-to-Sales) history and trend
- CDNA intrinsic value — DCF, Graham Number, EPV models
- CDNA stock price prediction 2025 2026 2027 2028 2029 2030
- CDNA fair value vs current price
- CDNA insider transactions and insider buying
- Is CDNA undervalued or overvalued?
- CareDx Inc financial analysis — revenue, earnings, cash flow
- CDNA Piotroski F-Score and Altman Z-Score
- CDNA analyst price target and Smart Rating
CareDx Inc
📊 No data available
Try selecting a different time range
Smart Analysis
CareDx Inc (CDNA) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around peg ratio and return on equity. Significant fundamental concerns warrant caution or avoidance.
CareDx Inc (CDNA) Key Strengths (2)
101.70% of shares held by major funds and institutions
Strong revenue growth at 25.20% annually
Supporting Valuation Data
CareDx Inc (CDNA) Areas to Watch (7)
PEG ratio is negative or unavailable
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Small-cap company with higher risk but more growth potential
Revenue is fairly priced at 2.32x sales
Fairly priced relative to book value
Supporting Valuation Data
CareDx Inc (CDNA) Detailed Analysis Report
Overall Assessment
This company scores 34/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 2 register as strengths (avg 9.0/10) while 7 fall into concern territory (avg 2.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Revenue Growth. Growth metrics are encouraging with Revenue Growth at 25.20%.
The Bear Case
The primary concerns are PEG Ratio, Return on Equity, Operating Margin. Some valuation metrics including PEG Ratio (N/A), Price/Sales (2.32), Price/Book (2.90) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -6.27%, Operating Margin at -3.49%, Profit Margin at -5.62%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -6.27% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 25.20% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. PEG Ratio and Return on Equity are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CDNA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CDNA's Price-to-Sales ratio of 2.32x trades at a deep discount to its historical average of 9.32x (19th percentile). The current valuation is 93% below its historical high of 31.15x set in Nov 2018, and 190% above its historical low of 0.8x in Oct 2023. Over the past 12 months, the PS ratio has compressed from ~2.8x as trailing revenue scaled faster than the stock price.
Compare CDNA with Competitors
Top DIAGNOSTICS & RESEARCH stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for CareDx Inc (CDNA) · HEALTHCARE › DIAGNOSTICS & RESEARCH
The Big Picture
CareDx Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 380M with 25% growth year-over-year. The company is currently unprofitable, posting a -5.6% profit margin.
Key Findings
Revenue growing at 25% YoY, reaching 380M. This pace significantly outperforms most DIAGNOSTICS & RESEARCH peers.
Generating 20M in free cash flow and 21M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -5.6% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Growth sustainability: can CareDx Inc maintain 25%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 2.58, so expect amplified moves relative to the broader market.
Sector dynamics: monitor DIAGNOSTICS & RESEARCH industry trends, competitive moves, and regulatory changes that could impact CareDx Inc.
Bottom Line
CareDx Inc offers an attractive blend of growth (25% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(21 last 3 months)
| Insider | Type | Shares |
|---|---|---|
NOVACK, JEFFREY ADAM Secretary and General Counsel | Sell | -4,441 |
| Insider | Type | Shares |
|---|---|---|
HANNA, JOHN WALTER JR Director, President and CEO | Sell | -19,280 |
| Insider | Type | Shares |
|---|---|---|
HANNA, JOHN WALTER JR Director, President and CEO | Sell | -200 |
| Insider | Type | Shares |
|---|---|---|
HANNA, JOHN WALTER JR Director, President and CEO | Sell | -10,156 |
| Insider | Type | Shares |
|---|---|---|
GOLDBERG, MICHAEL Director | Buy | +1,492 |
Data sourced from SEC Form 4 filings
Last updated: 8:28:14 AM
About CareDx Inc(CDNA)
NASDAQ
HEALTHCARE
DIAGNOSTICS & RESEARCH
USA
CareDx, Inc. discovers, develops and markets diagnostic solutions for transplant patients and caregivers globally. The company is headquartered in South San Francisco, California.